Megan Sykes

Medawar Prize Laureate (2018)

Introduction of Jean-Paul Soulillou, MD, Recipient of the 2016 Medawar Prize


It is indeed a pleasure for me to introduce Jean-Paul Soulillou as the Medawar Prize Winner for 2016. I have known Jean-Paul for many years and indeed in the past served on his Advisory Board for the Nantes Transplant Institute. As we had many overlapping interests in research, especially in tolerance induction, we have always kept a close eye on each other's work. He was also a visiting professor some years ago in my department at the University of Oxford, and so I feel well qualified to introduce him as this year's Medawar Prize winner.

Read More

Jean-Paul was born in Bordeaux in 1944and went to medical school in Bordeaux, and Nantes, graduating in 1968. He was a resident at the Nantes University Hospital and then spent a very interesting year in a “foreign organisation in healthcare” (like a French Peace Corps) in the mercury mines in Tunisia. This had quite an impact on his life, it being the first time he had been out of France and been exposed to healthcare in a poor country. At the end of his time there, he could question a patient in Arabic.

In 1974, he went to the Peter Brent Brigham Hospital as a research fellow to spend 15 months with Bernie Carpenter, and without question, this experience had a major impact on his whole future career. He also met his wife to be, Helga, in Boston, and she has been a great support for him ever since.

He returned to Nantes University, where by 1980, he had become Professor of Immunology. He was the founder and director of the prestigious Institute of Transplantation at the University of Nantes, a position he held from 1991 to 2010. He was also the founder and director of not 1, but 3 Institut National de la Santé et de la Recherche Medicalej (INSERM) units between 1986 and 2007. He also served on the external Advisory Board for the NIH Immune Tolerance Network and was the founder of 3 Biotech companies. He served on the editorial boards of a number of journals including the New England Journal of Medicine, American Journal of Transplantation, Transplant International, and Transplantation. He also founded the Nantes Actualitiés in Transplantation course which is held annually and remains extremely popular to this day.

As one might imagine, he has won quite a number of prizes for his work. For example, in 1998, he won the L. Binet Prize of the French Foundation of Medical Research; in 2002, the Eloi Collery Prize of the Academy of Medicine; in 2008, he was awarded The Transplantation Society Award for his outstanding achievement in transplantation science, and in 2012, he was awarded the prestigious Prix d'Honneur of INSERM (which is only given to 1 scientist each year) in recognition of his outstanding work with INSERM over many years.

He has published some 540 scientific articles, and of these, my favourites are his article in the New England Journal of Medicine in 1990 and also a follow-up in Lancet in 1997 showing that IL-2 receptor antibodies can prevent rejection; antibody to class II HLA antigens is associated with rejection (Lancet, 1978); the mechanism of immune tolerance and rejection (articles published in leading journals over many years) and another very important paper published in 1998 in the Lancet “Cancer after transplantation related to the weight of immunosuppression.”

Jean-Paul Soulillou is married to Helga, and has 3 children, Muriel, Adrien, and Marc. His only hobby is research, and he does not claim to have climbed Mount Everest, done white water rafting, played golf or, indeed, any of these rather macho pursuits, and he tells me that his only eccentricity is being French.

Jean-Paul Soulillou has been an outstanding clinical scientist in the field of transplantation, and Mr President, I cannot think of anyone worthier to be a recipient of the Medawar Prize.

Morris, Peter J.
Transplantation: December 2016 - Volume 100 - Issue 12 - p 2495-2497

The Medawar Prize Acceptance Speech 2016


Mister President, Chairman, Ladies and Gentlemen, Dear Colleagues and Friends.

I first would like to thank Sir Peter Morris, Prof, as I use to call him since a visiting professor stay on Oxford, for having accepted to introduce me to the audience and for his kind words. Needless to say how proud and grateful I feel for receiving this award. But I feel also very humble; humble not only in front of the iconic portrait of Peter Medawar of course but also in front of the gallery of the past Medawar Prize recipients. But more, I feel in front of this distinction as a kind of representative—only one of the several ambassadors of my generation.

Highlighted Articles


Hematopoietic Cell Transplantation for Tolerance Induction: Animal Models to Clinical Trials

Sykes, Megan
Transplantation: February 15, 2009 - Volume 87 - Issue 3 - p 309-316

The induction of donor-specific immune tolerance is the “holy grail” of transplantation, as it would avoid the toxicities of chronic immunosuppressive therapies while preventing acute and chronic graft rejection. A large number of approaches to tolerance induction have been described in the experimental literature, but only hematopoietic cell transplantation has shown preliminary success for intentional tolerance induction in pilot clinical trials. This review summarizes the conditions that allow progress to be made in moving strategies for tolerance induction from the bench to the bedside and discuss the mechanisms by which tolerance may be achieved through hematopoietic cell transplantation.

Commentary: World Health Assembly Resolution 57.18 on Xenotransplantation

Sykes, Megan
Transplantation: March 27th, 2005 - Volume 79 - Issue 6 - p 636-637

Clinical xenotransplantation provides a potentially promising solution to the shortage of human organs and tissues. However, the potential to introduce new infections from xenogeneic source animals into the human populace is a risk that has led several countries in North America, Europe, Asia, and Oceania to expend considerable efforts in the development of guidelines and oversight procedures for husbandry of source animals and xenotransplant recipient monitoring.

International cooperation on xenotransplantation

Megan Sykes, Mauro Sandrin & Emanuele Cozzi
Nature Medicine, volume 10, page 119 (2004)

We are writing on behalf of the Ethics Committee of the International Xenotransplantation Association (IXA). Our committee recently expressed concern about the need for international guidelines for overseeing clinical xenotransplantation. We have published letters in scientific journals and corresponded with representatives of the World Health Organization (WHO) regarding these concerns. Although clinical xenotransplantation provides a potentially promising solution to the shortage of human organs and tissues, the potential to introduce new infections from xenogeneic source animals into the human populace is a concern that mandates extreme caution.

Highlighted Videos


Megan Sykes, COVID-19 Virtual Symposium: April 8, 2020

Stanford Surgery

2018 Salvatierra Lecture: Megan Sykes, MD

Stanford Surgery

Dr. Megan Sykes: Customized Mouse May Improve Cancer Therapy Response

Columbia Doctors - 2016

Megan Sykes, MD, on transplantation research

Vagelos College of Physicians & Surgeons, Columbia - 2015

Megan Sykes (Columbia U.) 1: Introduction to Transplantation

iBiology - 2013

Megan Sykes, MD Introduction

Naomi Berrie Diabetes Center at Columbia University - 2013

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada